These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20211900)

  • 21. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration.
    Gill MM; Rao JU; Kaleem F; Hassan A; Khalid A; Anjum R
    Pak J Pharm Sci; 2013 Jan; 26(1):7-10. PubMed ID: 23261721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.
    Bergen PJ; Bulitta JB; Forrest A; Tsuji BT; Li J; Nation RL
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3783-9. PubMed ID: 20585118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
    Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.
    Grégoire N; Raherison S; Grignon C; Comets E; Marliat M; Ploy MC; Couet W
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2379-84. PubMed ID: 20368392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
    Mori N; Ishii Y; Tateda K; Kimura S; Kouyama Y; Inoko H; Mitsunaga S; Yamaguchi K; Yoshihara E
    J Antimicrob Chemother; 2012 Sep; 67(9):2173-81. PubMed ID: 22628248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.
    Bergen PJ; Li J; Rayner CR; Nation RL
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1953-8. PubMed ID: 16723551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2013 May; 57(5):2310-8. PubMed ID: 23478951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal effect of colistin on planktonic Pseudomonas aeruginosa is independent of hydroxyl radical formation.
    Brochmann RP; Toft A; Ciofu O; Briales A; Kolpen M; Hempel C; Bjarnsholt T; Høiby N; Jensen PØ
    Int J Antimicrob Agents; 2014 Feb; 43(2):140-7. PubMed ID: 24315789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes.
    Pamp SJ; Gjermansen M; Johansen HK; Tolker-Nielsen T
    Mol Microbiol; 2008 Apr; 68(1):223-40. PubMed ID: 18312276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.
    Tam VH; Schilling AN; Vo G; Kabbara S; Kwa AL; Wiederhold NP; Lewis RE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3624-30. PubMed ID: 16127031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.
    Ly NS; Yang J; Bulitta JB; Tsuji BT
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3453-6. PubMed ID: 22470116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea.
    Lee YC; Ahn BJ; Jin JS; Kim JU; Lee SH; Song DY; Lee WK; Lee JC
    J Microbiol; 2007 Aug; 45(4):358-63. PubMed ID: 17846591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea.
    Lee JY; Song JH; Ko KS
    Microb Drug Resist; 2011 Jun; 17(2):299-304. PubMed ID: 21381965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.